Trials / Completed
CompletedNCT02560948
Clinical Efficacy and Safety of a Subcutaneous Immunotherapy With gpASIT+™ in Patients With Grass Pollen-induced Allergic Rhinoconjunctivitis
A Multicenter, International, Randomised, Double-blind, Placebo Controlled Study to Demonstrate the Clinical Efficacy and Safety of a Subcutaneous Immunotherapy With gpASIT+™ in Patients With Grass Pollen-induced Allergic Rhinoconjunctivitis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 554 (actual)
- Sponsor
- BioTech Tools S.A. · Industry
- Sex
- All
- Age
- 18 Years – 64 Years
- Healthy volunteers
- Not accepted
Summary
gpASIT+TM product is based on highly purified allergen fragments obtained from grass pollen. The purpose of this study is to demonstrate the clinical efficacy and safety of a subcutaneous immunotherapy with gpASIT+™ in patients with grass pollen-induced allergic rhinoconjunctivitis compared to placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Placebo solution | 4 x 2 injections over 21 days |
| BIOLOGICAL | gpASIT+TM | 4 x 2 injections over 21 days |
Timeline
- Start date
- 2015-12-01
- Primary completion
- 2016-08-01
- Completion
- 2016-08-01
- First posted
- 2015-09-25
- Last updated
- 2018-10-11
Locations
3 sites across 3 countries: Belgium, Italy, Spain
Source: ClinicalTrials.gov record NCT02560948. Inclusion in this directory is not an endorsement.